Early Tranexamic Acid and Modulating the Inflammatory Response in Sepsis

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Sepsis

In brief

In this study, our aim is to investigate the role tranexamic acid in modulating inflammation in patients with sepsis.

Key facts

Study ID

NCT04910464

Run by

Assiut University

People needed

80

Starts

2021-06-05

Expected to finish

2027-01-30

Last updated by the study team

2025-08-05

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (age 18-65 years) of American society of anesthesiologists (ASA) I-II who will be diagnosed with sepsis by qSOFA ≥2
• \& needed ICU admission.

You may not qualify if…

• Chronic renal failure
• Liver cirrhosis
• Bleeding disorders or current anticoagulant therapy
• Pregnancy or breastfeeding
• Impaired color vision
• Severe vascular ischemia, history of venous thrombosis \& pulmonary embolism
• Long term treatment with acetylsalicylic acid or non-steroidal anti-inflammatory drugs not discontinued before ICU admission
• Allergy to tranexamic acid (TXA)

Where it is running

• Assiut university hospital — Asyut, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.